Navigation Links
inVentiv Health Strengthens Clinical Leadership Team
Date:12/10/2012

BURLINGTON, Mass., Dec. 10, 2012 /PRNewswire/ -- inVentiv Health, Inc., offering best-in-class clinical, commercial and consulting services to the healthcare industry, today announced organizational changes within its clinical group. Raymond Hill is joining the Company as Executive Vice President of Clinical, effective December 12, 2012, and will be responsible for leading the Company's Clinical business segment, which includes Early Stage, Phase II-IV and Strategic Resourcing.

"We are very pleased to welcome a seasoned industry veteran like Ray to inVentiv and expect that his significant experience in both successfully growing pharmaceutical services businesses and leading productive teams will be an asset to our organization," said Paul Meister, Chief Executive Officer at inVentiv. 

Prior to joining inVentiv, Hill was CEO at Pharmaceutical Product Development, Inc., where he successfully oversaw the process of taking the company private. Before that, he was President at IMS Consulting Group, where he oversaw an aggressive strategy of organic and inorganic growth – building the business from $100M in 2004 to $500M in 2010. Prior to IMS, Hill held a series of other positions in pharmaceutical consulting.  He earned a Bachelor's Degree from Cornell University and a Master's Degree from Duke University.

About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to companies seeking to accelerate performance. inVentiv offers convergent services that deliver extraordinary outcomes to clients whose goal is improving human life. In 40 countries around the world, inVentiv's 13,000 employees help clients rapidly transform promising ideas into commercial reality. inVentiv clients include more than 550 pharmaceutical, biotech and life sciences companies, as well as companies that now see health as part of their mission. inVentiv Health Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. For more information, visit http://www.inventivhealth.com.    

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of the consummation of any announced  and future acquisitions; the impact of any change in our ratings and the ratings of our debt securities on our relationships with customers, vendors and other third parties;  the impact of any additional leverage we may incur on our ratings and the ratings of our debt securities; our ability to sufficiently increase our revenues and maintain or decrease expenses and cash capital expenditures to permit us to fund our operations; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact of pricing pressures on pharmaceutical manufacturers from future healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and achieve the resulting synergies; the resolution of purchase price adjustment disputes in connection with our recent acquisitions and related impacts; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base; our ability to comply with all applicable laws as well as our ability to successfully implement from a timing and cost perspective any changes in applicable laws; our ability to recruit, motivate and retain qualified personnel, including sales representatives; the possibility that client agreements will be terminated or not renewed; any potential impairment of goodwill or intangible assets; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; the impact of customer project delays and cancellations; our ability to convert backlog into revenue; the potential liability associated with injury to clinical trial participants; the actual impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memorandums provided in connection with the issuance of our senior secured notes for further discussion of these risks and other factors.


'/>"/>
SOURCE inVentiv Health, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. inVentiv Medical Management Forms Partnership with Vital Decisions
2. USANA True Health Foundation: Musician Donates Proceeds Of Holiday Song To Charity
3. Henry Schein To Present At The Oppenheimer 23rd Annual Healthcare Conference
4. Health Outcomes Liaisons Key to Pharmaceutical Sector Navigating Payer-Focused Marketplace
5. Aratana to Present at Bank of America Merrill Lynch Animal Health Summit
6. The First Lean Healthcare App is Now Available in Apples App Store
7. Accuray Incorporated to Speak at 23rd Annual Oppenheimer Healthcare Conference
8. Jardogs Strengthens Leadership Team with the Addition of Two Seasoned Healthcare Executives
9. Verizon, Healthsense Bring Home-Health Solutions to a Top Retirement Community in Virginia
10. HeartWare Presentation at the Oppenheimer 23rd Annual Healthcare Conference to be Webcast
11. Suture Express Files Antitrust Lawsuit Against Cardinal Health and Owens & Minor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... , Feb. 10, 2016  The Baylor ... received an in-kind gift from ... VeinViewer® Vision vein finder for the nursing ... students as they learn how to start ... with traditional technique. ...
(Date:2/10/2016)... Feb. 10, 2016  Visage Imaging Inc. ("Visage"), ... (ASX: PME), has announced that the American College of ... have selected the Visage 7 Enterprise Imaging Platform ... Emergent/Critical Care Imaging SIMulation (SIM). SIM is the ... Program (WIDI), a multi-faceted and fully-integrated online assessment, ...
(Date:2/10/2016)... -- Mast Therapeutics, Inc. (NYSE MKT: MSTX), ... cell disease and heart failure, today announced the pricing ... a price to the public of $0.275 per unit. ... common stock and one warrant to purchase one share ... of $0.42 per share. The warrants are exercisable six ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... , ... Emergency rooms provide emergency care to stabilize critical health issues, but ... dental emergencies at risk of losing a tooth or their smiles. Dr. Marine Martirosyan, ... dental emergencies include:, , Avulsed or knocked-out teeth , ...
(Date:2/10/2016)... Missouri (PRWEB) , ... February 10, 2016 , ... ... in San Diego, will bring together more than 200 of the country’s top ... for the future. , “The true benefit of the Forum is the provider-centric ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... time Emmy award winner and inspirational speaker Jan Fox will serve as keynote ... Speaking Boldly will provide participants with tools to more effectively communicate with their ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... Everseat digital self-scheduling readily available to physicians. The integration will enable ... find and select appointments via Everseat’s free mobile app. , The partnership gives ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... The recreational ... cannabis enthusiasts in the state still face a lot of restrictions as to where ... is intended for private, personal use” and that cannabis “may not be consumed openly ...
Breaking Medicine News(10 mins):